Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

Mifepristone 2Corlux 2tariquidar 1relacorilant 1pembrolizumab 1cabozantinib 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adrenal Cortex Neoplasms × cabozantinib × Clear all
NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 5 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡